Search Result

Results for "

immune modulation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (3) Bacterial (1) c-Fms (1) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (1) Fungal (1) HIV (3) Interleukin Related (2) MAP4K (1) NOD-like Receptor (NLR) (1) Phosphodiesterase (PDE) (3)
By Research Areas:	Cancer (10) Cardiovascular Disease (3) Infection (1) Inflammation/Immunology (9) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147228

NR2F6 modulator-1	Others	Inflammation/Immunology Cancer
NR2F6 modulator-1 is a potent nuclear receptor subfamily 2, group F, member 6 (NR2F6) modulator. NR2F6 modulator-1 can be used for researching immune modulation and modulation of cancer stem cell activity .

HY-129055

Isoeleutherin	Fungal	Inflammation/Immunology
Isoeleutherin is a naphthopyran derivative isolated from E. americana Merr. Et Heyne with anti-fungal, anti-viral, and anti-tumor activities. Isoeleutherin plays an important role in selective modulation of T helper cell-mediated immune responses .

HY-155120

Cbl-b-IN-5	E1/E2/E3 Enzyme	Inflammation/Immunology Cancer
Cbl-b-IN-5 (compound 6) is a Cbl-b inhibitor (IC₅₀=3-10 µM). Cbl-b-IN-5 has the potential to be used in the study of cancer and related diseases amenable to immune system modulation .

HY-163494

NLRP3-IN-36

NOD-like Receptor (NLR) Inflammation/Immunology

NLRP3-IN-36 (Compound 111) is an NLRP3 inhibitor (IC₅₀ <1 μM) .
HY-163495

HPK1-IN-44

MAP4K Inflammation/Immunology Cancer

HPK1-IN-44 (Compound 1) is an inhibitor of HPK1 (IC₅₀=0.1 nM (40 μM ATP)) .

NLRP3-IN-36	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-36 (Compound 111) is an NLRP3 inhibitor (IC₅₀ <1 μM) .

HPK1-IN-44	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-44 (Compound 1) is an inhibitor of HPK1 (IC₅₀=0.1 nM (40 μM ATP)) .

HY-141431

Cbl-b-IN-2	E3 Ligase Ligand-Linker Conjugates	Inflammation/Immunology Cancer
Cbl-b-IN-2 (Example 8) is an orally bioavailable compound, can inhibit the E3 enzyme Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) in the ubiquitin proteasome pathway. Cbl-b-IN-2 can be used to modulate the immune system and diseases amenable to immune system modulation. Cbl-b-IN-2 (Example 8) also may be administered to an individual with cancer, either alone or as part of a combination, with one or more of an immune checkpoint inhibitor, an anti-neoplastic agent, and radiation agent .

HY-B0715

Pentoxifylline 5+ Cited Publications BL-191; PTX; Oxpentifylline	Phosphodiesterase (PDE) Autophagy HIV	Cardiovascular Disease Cancer
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

HY-P2320

IDR-1	Bacterial	Infection Inflammation/Immunology
IDR-1 is an antimicrobial peptide that is active against Gram-positive and Gram-negative bacteria. IDR-1 counters infection by selective modulation of innate immunity without obvious toxicities. IDR-1 has anti-inflammatory and anti-infective properties, enhances the levels of monocyte chemokines, and attenuates pro-inflammatory cytokine release .

HY-B0715S

Pentoxifylline-d6 BL-191-d₆; PTX-d₆; Oxpentifylline-d₆	Phosphodiesterase (PDE) Autophagy HIV	Cardiovascular Disease Cancer
Pentoxifylline-d₆ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

HY-B0715S2

Pentoxifylline-d5 BL-191-d₅; PTX-d₅; Oxpentifylline-d₅	Phosphodiesterase (PDE) Autophagy HIV	Cardiovascular Disease Cancer
Pentoxifylline-d₅ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

HY-162415

CSF1R-IN-22	c-Fms Apoptosis	Cancer
CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC₅₀<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8 ^{+ ^{T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8 ^{+ ^{T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs .}}}}

HY-145429

IL-17A modulator-2	Interleukin Related	Neurological Disease Inflammation/Immunology Cancer
IL-17A modulator-2 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 27. IL-17A modulator-2 inhibits the biological action of IL-17A with a pIC₅₀ of 8.3. IL-17A modulator-2 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders .

HY-145430

IL-17A modulator-1	Interleukin Related	Neurological Disease Inflammation/Immunology Cancer
IL-17A modulator-1 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 9. IL-17A modulator-1 inhibits the biological action of IL-17A with a pIC₅₀ of 8.2. IL-17A modulator-1 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders .

IDR-1	Bacterial	Infection Inflammation/Immunology
IDR-1 is an antimicrobial peptide that is active against Gram-positive and Gram-negative bacteria. IDR-1 counters infection by selective modulation of innate immunity without obvious toxicities. IDR-1 has anti-inflammatory and anti-infective properties, enhances the levels of monocyte chemokines, and attenuates pro-inflammatory cytokine release .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-129055

Isoeleutherin	Quinones Iridaceae Classification of Application Fields Source classification Eleutherine plicata Herb. Plants Naphthalene Quinones Disease Research Fields Inflammation/Immunology	Fungal
Isoeleutherin is a naphthopyran derivative isolated from E. americana Merr. Et Heyne with anti-fungal, anti-viral, and anti-tumor activities. Isoeleutherin plays an important role in selective modulation of T helper cell-mediated immune responses .

HY-B0715

Pentoxifylline 5+ Cited Publications BL-191; PTX; Oxpentifylline	Classification of Application Fields Disease Research Fields Cancer	Phosphodiesterase (PDE) Autophagy HIV
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

Cat. No.	Product Name	Chemical Structure

HY-B0715S

Pentoxifylline-d6
Pentoxifylline-d₆ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

Pentoxifylline-d6

Pentoxifylline-d₆ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

HY-B0715S2

Pentoxifylline-d5
Pentoxifylline-d₅ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

Pentoxifylline-d5

Pentoxifylline-d₅ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks